Chiusura precedente | 1,5140 |
Aperto | 1,5140 |
Denaro | 1,4780 x 0 |
Lettera | 1,7020 x 0 |
Min-Max giorno | 1,5140 - 1,5940 |
Intervallo di 52 settimane | 1,3620 - 4,5500 |
Volume | |
Media Volume | 7 |
Capitalizzazione | N/D |
Beta (5 anni mensile) | N/D |
Rapporto PE (ttm) | N/D |
EPS (ttm) | N/D |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Bexmarilimab produces a 50% remission rate in doublet dose cohorts (11 out of 22 patients)Eight of the 11 patients are Complete Responders (CR) or CR with incomplete blood recovery (CRi)Highest overall response rate (ORR) of 80% observed in prior HMA-failure MDS group (4 out of 5 patients)Bexmarilimab continues to be well-tolerated with no dose-limiting toxicity observedCompany to host virtual investor call to discuss data, today at 8:00 am EST Company announcement, Inside Information TURKU, Fin
TURKU, Finland and BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pioneering macrophage re-programming for effective cancer immunotherapies, today announces it will host a virtual call for investors to provide an update on the most recent Phase I/II BEXMAB data in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) on Wednesday, October 11 at 08.00 EST/13.00 BST/15.00 EEST. The new data co
TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, is pleased to announce the appointment of Ms. Christine Roth and Dr. Marie-Louise Fjällskog as Non-Executive Directors of the Company with immediate effect following the passing of all resolutions put to shareholders of the Company at the Extraordinary General Meeting held earlie